Efficacy of transarterial embolization with arsenic trioxide oil emulsion in a rabbit VX2 liver tumor model.
OBJECTIVE
To investigate the anticancer activity of transarterial embolization with arsenic trioxide (As(2)O(3)) oil emulsion, as well as its hepatic and renal toxicity, in a rabbit VX2 liver model.


METHODS
VX2 carcinomas were grown in rabbit livers, followed by transarterial embolization with high-dose As(2)O(3) (5 mg/kg with 0.2 mL Lipiodol, n = 7), low-dose As(2)O(3) (1 mg/kg with 0.2 mL Lipiodol, n = 7), or control (0.2 mL Lipiodol, n = 7). The growth ratios and residual viable proportions of the tumors were estimated by multi-detector row computed tomography and histopathologic examination, respectively. Hepatic and renal toxicity was evaluated by means of blood biochemical analysis.


RESULTS
The growth ratios of the tumors differed significantly among the three groups (P = .008). The high-dose As(2)O(3) group showed significantly lower tumor growth ratios than the control group (mean +/- SD, 14.8% +/- 78.6 vs 794.0% +/- 156.2; P = .008). The residual viable proportions of the tumors were significantly lower in the high-dose (9.5% +/- 8.8) and low-dose (13.0% +/- 9.1) As(2)O(3) groups than in the control group (44.5% +/- 5.2; P < .017). Blood chemical concentrations indicating hepatic and renal toxicity did not differ among the three groups before or after transarterial embolization (P > .05).


CONCLUSIONS
Transarterial embolization with As(2)O(3) iodized oil emulsion in rabbit VX2 liver tumors has anticancer effects without significant increase in hepatic and renal toxicity.
Kim
Hye Jin
HJ
Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Shin
Ji Hoon
JH
Kim
Tae-Hyung
TH
Kim
Eun Young
EY
Park
Young Soo
YS
Park
Chan-Sik
CS
Song
Ho-Young
HY
D000818:Animals; D001151:Arsenic / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods; D004655:Emulsions; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007459:Iodized Oil / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D011817:Rabbits; D016896:Treatment Outcome
D004655:Emulsions; D006490:Hemostatics; D007459:Iodized Oil; D001151:Arsenic